A study of SCR-6920 capsule in patients with advanced malignant tumors

illustrative image

Jiangsu Simcere Pharmaceutical Co., Ltd is starting a new clinical trial of A Study to Investigate the Safety and Tolerability of SCR-6920 Capsule in Patients With Advanced Malignant Tumors.

A Phase 1, open label, multi center, dose escalation and expansion study will assess the safety, tolerability, PK, and preliminary efficacy of SCR-6920 capsule in participants with advanced malignant tumors. The purpose of the study is to identify the maximum tolerated dose (MTD) and/or the recommended Phase 2 dose (RP2D), and to confirm the tolerability and preliminary efficacy of SCR-6920 in participants with advanced solid tumors and relapsed/refractory non-Hodgkin lymphoma(NHL).

The clinical trial started in May 18, 2022 and will continue throughout October 2027.

Dose limiting toxicity(DLT) will be primary outcome measure. DLT will be evaluated within 28 days since first dose. The number of DLTs will be used to determine the maximum tolerated dose (MTD).

The location is Shandong Cancer Hospital, Jinan, Shandong, China. For more details: https://ichgcp.net/clinical-trials-registry/NCT05528055.

Clinical Research News

Upcoming Clinical Trials

3